ALT - INVESTOR ALERT: Edelson Lechtzin LLP Urges Altimmune Inc. (NASDAQ: ALT) Shareholders With Substantial Losses To Consult Counsel About The Pending Securities Fraud Class Action | Benzinga

NEWTOWN, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a leading class action law firm, is investigating alleged violations of the federal securities laws by certain officers and directors of Altimmune, Inc. (NASDAQ:ALT).

Investors who purchased Altimmune, Inc. stock between December 1, 2023, and April 26, 2024, inclusive (the "Class Period") have until July 5, 2024, to move the U.S. District Court for the District of Maryland to appoint them as lead plaintiff in the pending securities fraud class action lawsuit.

To learn more about this case, please contact Eric Lechtzin of Edelson Lechtzin LLP at 844-696-7492 or by e-mail at elechtzin@edelson-law.com. A copy of the class action complaint can be viewed HERE.

Background on Altimmune, Inc.

Headquartered in Gaithersburg, Maryland, Altimmune is a biopharmaceutical company developing innovative peptide-based therapeutics, including pemvidutide, a dual receptor agonist for obesity and MASH.

The Securities Fraud Claims

The Complaint alleges claims that throughout the Class Period, Defendants made materially false and/or misleading statements regarding the Company's business, operations, and prospects including that: (i) Altimmune exaggerated pemvidutide's potential to outperform competing GLP-1 agonists based on the ...

ALT) Shareholders With Substantial Losses To Consult Counsel About The Pending Securities Fraud Class Action>Full story available on Benzinga.com